NSAID use reduces breast cancer recurrence in overweight and obese women: Role of prostaglandin-aromatase interactions

Cancer Research

Volumn 74, Issue 16, 2014, Pages 4446-4457

  Bowers, Laura W ^a   Maximo, Ilane X F ^a   Brenner, Andrew J ^b   Beeram, Muralidhar ^c   Hursting, Stephen D ^a   Price, Ramona S ^a   Tekmal, Rajeshwar R ^c   Jolly, Christopher A ^a   DeGraffenried, Linda A ^a  

^a The University of Texas at Austin   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE; CYCLOOXYGENASE 2; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA, HUMAN; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E2; PTGS2 PROTEIN, HUMAN;

BREAST NEOPLASMS; CELL GROWTH; CELL MOTION; COMPLICATION; DISEASE FREE SURVIVAL; DRUG EFFECTS; ENZYMOLOGY; FEMALE; HUMAN; MACROPHAGE; METABOLISM; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OBESITY; RETROSPECTIVE STUDY;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AROMATASE; BREAST NEOPLASMS; CELL GROWTH PROCESSES; CELL MOVEMENT; CYCLOOXYGENASE 2; DINOPROSTONE; DISEASE-FREE SURVIVAL; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; MACROPHAGES; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OBESITY; OVERWEIGHT; RETROSPECTIVE STUDIES;

EID: 84905982814     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-3603     Document Type: Article

References (50)

1. World Health Organization [Internet]. World Health Statistics 2012. Available from: http://www.who.int/gho/publications/world-health--statistics/ 2012/en/. [accessed October 1, 2013].
2. Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA 2012;307:491-7.
3. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003;348:1625-38. (Pubitemid 36459468)
4. Senie RT, Rosen PP, Rhodes P, Lesser ML, Kinne DW. Obesity at diagnosis of breast carcinoma influences duration of disease-free survival. Ann Intern Med 1992;116:26-32.
5. Majed B, Moreau T, Senouci K, Salmon RJ, Fourquet A, Asselain B. Is obesity an independent prognosis factor in woman breast cancer? Breast Cancer Res Treat 2008;111:329-42.
6. Chlebowski RT, Aiello E, McTiernan A. Weight loss in breast cancer patient management. J Clin Oncol 2002;20:1128-43. (Pubitemid 34141858)
7. Protani M, Coory M, Martin JH. Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat 2010;123:627-35.
8. Sestak I, Distler W, Forbes JF, Dowsett M, Howell A, Cuzick J. Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial. J Clin Oncol 2010;28:3411-5.
9. Schmid P, Possinger K, Bohm R, Chaudri H, Verbeek A, Grosse Y, et al. Body mass as predictive parameter for response and time to progression (TTP) in advanced breast cancer patients treated with letrozole or megestrol acetate. In Proceedings of the Annual Meeting of the American Society of Clinical Oncology: 2000 May 20-23; New Orleans 2000:19.
10. Folkerd EJ, Dixon JM, Renshaw L, A'Hern RP, Dowsett M. Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer. J Clin Oncol 2012;30:2977-80.
11. Jonat W, Howell A, Blomqvist C, Eiermann W, Winblad G, Tyrrell C, et al. A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer 1996;32A:404-12.
12. Buzdar AU, Jones SE, Vogel CL, Wolter J, Plourde P, Webster A. A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group. Cancer 1997;79:730-9. (Pubitemid 27076339)
13. Subbaramaiah K, Morris PG, Zhou XK, Morrow M, Du B, Giri D, et al. Increased levels of COX-2 and prostaglandin E2 contribute to elevated aromatase expression in inflamed breast tissue of obese women. Cancer Discov 2012;2:356-65.
14. Morris PG, Hudis CA, Giri D, Morrow M, Falcone DJ, Zhou XK, et al. Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer. Cancer Prev Res 2011;4:1021-9.
15. Subbaramaiah K, Howe LR, Bhardwaj P, Du B, Gravaghi C, Yantiss RK, et al. Obesity is associated with infl ammation and elevated aromatase expression in the mouse mammary gland. Cancer Prev Res 2011;4:329-46.
16. Obiorah I, Jordan VC. Progress in endocrine approaches to the treatment and prevention of breast cancer. Maturitas 2011;70:315-21.
17. Fisher B, Jeong JH, Bryant J, Anderson S, Dignam J, Fisher ER, et al. Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Lancet 2004;364:858-68. (Pubitemid 39221063)
18. Garcia-Closas M, Brinton LA, Lissowska J, Chatterjee N, Peplonska B, Anderson WF, et al. Established breast cancer risk factors by clinically important tumour characteristics. Br J Cancer 2006;95:123- 9.
19. Ghosh S, Choudary A, Ghosh S, Musi N, Hu Y, Li R. IKKb mediates cell shape-induced aromatase expression and estrogen biosynthesis in adipose stromal cells. Mol Endocrinol 2009;23:662-70.
20. Collison LW, Collison RE, Murphy EJ, Jolly CA. Dietary n-3 polyunsaturated fatty acids increase T-lymphocyte phospholipid mass and acyl-CoA binding protein expression. Lipids 2005;40:81-7. (Pubitemid 40395205)
21. Bowers LW, Cavazos DA, Brenner AJ, Hursting SD, Maximo IX, Degraffenried LA. Obesity enhances nongenomic estrogen receptor crosstalk with the PI3K/Akt and MAPK pathways to promote in vitro measures of breast cancer progression. Breast Cancer Res 2013;15:R59.
22. Price RS, Cavazos DA, De Angel RE, Hursting SD, deGraffenried LA. Obesity-related systemic factors promote an invasive phenotype in prostate cancer cells. Prostate Cancer Prostatic Dis 2012;15:135-43.
23. Holmes MD, Chen WY, Li L, Hertzmark E, Spiegelman D, Hankinson SE. Aspirin intake and survival after breast cancer. J Clin Oncol 2010;28:1467-72.
24. Kwan ML, Habel LA, Slattery ML, Caan B. NSAIDs and breast cancer recurrence in a prospective cohort study. Cancer Causes Control 2007;18:613-20. (Pubitemid 46883678)
25. Blair CK, Sweeney C, Anderson KE, Folsom AR. NSAID use and survival after breast cancer diagnosis in post-menopausal women. Breast Cancer Res Treat 2007;101:191-7. (Pubitemid 46115425)
26. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998;38:97-120. (Pubitemid 28231490)
27. Maihofner C, Charalambous MP, Bhambra U, Lightfoot T, Geisslinger G, Gooderham NJ. Expression of cyclooxygenase-2 parallels expression of interleukin-1β, interleukin-6, and NK-κB in human colorectal cancer. Carcinogenesis 2003;24:665-71. (Pubitemid 36592401)
28. Chow LW, Yip AY, Loo WT, Lam CK, Toi M. Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer. J Steroid Biochem Mol Biol 2008;111:13-7.
29. Dirix LY, Ignacio J, Nag S, Bapsy P, Gomez H, Raghunadharao D, et al. Treatment of advanced hormone-sensitive breast cancer in postmenopausal women with exemestane alone or in combination with celecoxib. J Clin Oncol 2008;26:1253-9.
30. Falandry C, Debled M, Bachelot T, Delozier T, Crétin J, Romestaing P, et al. Celecoxib and exemestane versus placebo and exemestane in postmenopausal metastatic breast cancer patients: a double-blind phase III GINECO study. Breast Cancer Res Treat 2009;116:501-8.
31. Hellmann J, Zhang MJ, Tang Y, Rane M, Bhatnagar A, Spite M. Increased saturated fatty acids in obesity alter resolution of inflammation in part by stimulating prostaglandin production. J Immunol 2013;191:1383-92.
32. Nicklas BJ, Rogus EM, Colman EG, Goldberg AP. Visceral adiposity, increased adipocyte lipolysis, and metabolic dysfunction in obese postmenopausal women. American J Physiol 1996;270:E72-8.
33. Bjorntorp P, Bergman H, Varnauskas E. Plasma free fatty acid turnover rate in obesity. Acta Med Scand 1969;185:351-6.
34. Jensen MD, Haymond MW, Rizza RA, Cryer PE, Miles JM. Influence of body fat distribution on free fatty acid metabolism in obesity. J Clin Invest 1989;83:1168-73. (Pubitemid 19113028)
35. Falcone DJ, Sakamoto J, Steenport ML, Khan KM, Du B, Dannenberg AJ. Interleukin 6 stimulates macrophage MMP-9 expression via COX-2 dependent induction of PGE2 synthesis and engagement of the EP4 receptor. FASEB J 2007;21:383.3.
36. Geng Y, Blanco FJ, Cornelisson M, Lotz M. Regulation of cyclooxygenase-2 expression in normal human articular chondrocytes. J Immunol 1995;155:796-801.
37. Murphey LJ, Williams MK, Sanchez SC, Byrne LM, Csiki I, Oates JA, et al. Quantification of the major urinary metabolite of PGE2 by a liquid chromatographic/mass spectrometric assay: determination of cyclooxygenase- specific PGE2 synthesis in healthy humans and those with lung cancer. Anal Biochem 2004;334:266-75. (Pubitemid 39370961)
38. Morris PG, Zhou XK, Milne GL, Goldstein D, Hawks LC, Dang CT, et al. Increased levels of urinary PGE-M, a biomarker of inflammation, occur in association with obesity, aging, and lung metastases in patients with breast cancer. Cancer Prev Res 2013;6:428-36.
39. McTiernan A, Wu L, Chen C, Chlebowski R, Mossavar-Rahmani Y, Modugno F, et al. Relation of BMI and physical activity to sex hormones in postmenopausal women. Obesity 2006;14:1662 -77.
40. Hankinson SE, Willett WC, Manson JE, Hunter DJ, Colditz GA, Stampfer MJ, et al. Alcohol, height, and adiposity in relation to estrogen and prolactin levels in postmenopausal women. J Natl Cancer Inst 1995;87:1297-302.
41. Cauley JA, Gutai JP, Kuller LH, LeDonne D, Powell JG. The epidemiology of serum sex hormones in postmenopausal women. Am J Epidemiol 1989;129:1120-31. (Pubitemid 19148455)
42. Larkins TL, Nowell M, Singh S, Sanford GL. Inhibition of cyclooxy-genase- 2 decreases breast cancer cell motility, invasion and matrix metalloproteinase expression. BMC Cancer 2006;6:181.
43. Singh B, Berry JA, Shoher A, Ramakrishnan V, Lucci A. COX-2 overexpression increases motility and invasion of breast cancer cells. Int J Oncol 2005;26:1393-9.
44. Bocca C, Bozzo F, Bassignana A, Miglietta A. Antiproliferative effects of COX-2 inhibitor celecoxib on human breast cancer cell lines. Mol Cell Biochem 2011;350:59-70.
45. Zhu XG, Tao L, Mei ZR, Wu HP, Jiang ZW. Aspisol inhibits tumor growth and induces apoptosis in breast cancer. Exp Oncol 2008;30:289-94.
46. Robertson FM, Simeone AM, Mazumdar A, Shah AH, McMurray JS, Ghosh S, et al. Molecular and pharmacological blockade of the EP4 receptor selectively inhibits both proliferation and invasion of human inflammatory breast cancer cells. J Exper Ther Oncol 2008;7:299-312.
47. Simmons DL, Botting RM, Hla T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev 2004;56:387-437. (Pubitemid 39096597)
48. Hwang D, Scollard D, Byrne J, Levine E. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst 1998;90:455-60. (Pubitemid 28160637)
49. Jeong HS, Kim JH, Choi HY, Lee ER, Cho SG. Induction of cell growth arrest and apoptotic cell death in human breast cancer MCF-7 cells by the COX-1 inhibitor FR122047. Oncol Rep 2010;24:351-6.
50. McFadden DW, Riggs DR, Jackson BJ, Cunningham C. Additive effects of Cox-1 and Cox-2 inhibition on breast cancer in vitro. Int J Oncol 2006;29:1019-23.